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Figure S1. DC101 treatment does not show anti-metastatic 
activity in an experimental i.v. model of lung metastasis. 4T1 
cells were injected in the tail vein and lung metastases let to 
develop for 9 days. Treatment with DC101 or IgG isotype control 
was initiated at day 1 post cancer cell inoculation and followed the 
same schedule as for the orthotopic model. Quantification of lung 
metastasis nodules in the two treatment groups. Ten mice per 
group were used.  
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Figure S2. Representative images of flow cytometry dot plots to demonstrate 
the gating strategy used for the analysis of MDSC in 4T1 tumor  bearing 
mice. A:  SSC/FSC gating of lymphocytes/monocytes isolated from tumors. B: 
FSC-A/FSCH gating to exclude doublets from the cell population of interest. C: 
CD45+ cells, were gated for further analysis. D: CD11b Gr1 double staining of 
CD45+ cells. Gated populations indicate CD11b+Gr1Low and CD11b+Gr1High cells. E-
F: Ly6C and  Ly6G double staining of CD11b+Gr1High and CD11b+ Gr1Low cells 
respectively define the mDSC (CD11b+ Gr1LowLy6C+) and gMDSC (CD11b+Gr1High 
Ly6G+) cell populations analyzed in this study.   
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Figure S3. DC101 treatment does not alter the frequency of circulating CD11b+ 
cells. Frequency of CD11b+ cells in the blood (A, day 22), in the spleens (B), in primary 
tumors (C) in metastatic lungs (D) of mice treated with DC101 (4T1+DC101) or IgG 
control (4T1+control IgG) antibodies. N=3, mice analyzed per group=8-20. 
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Figure S4. Effect of DC101 treatment on the expression of Arg I, iNOS, MRC1, VEGFR-2, 
IL10, IL12b, TNFα mRNA expression in CD11b+ and CD11b+Gr1+ cells in blood and tumor. A: 
Relative mRNA expression level for the indicated genes in blood circulating CD11b+ cells. Mice 
analyzed per group= 4-5. B: Same analysis for tumor-derived CD11b+ cells. Cells were positively 
isolated from DC101-treated (4T1+DC101) or IgG control-treated (4T1+control IgG) mice by 
MACS. Mice analyzed per group= 9-10. C: Same analysis for tumor-derived CD11b+Gr1+ cells. 
Cells derived from both treatment groups were positively isolated by MACS and subsequently 
sorted by FACS.  mRNA expression was measured by real time RT-PCR. Mice analyzed per 
group= 4-5. For each gene the value in control treated mice was set equal to 1.  
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Figure S5. Arg I expression in CD11b+ cells. A: CD11b+ cells are the main source of Arg I 
in the tumor microenvironment. CD11b+ and CD11b- cells were MACS sorted from 
dissociated tumors and analyzed for Arg I mRNA expression by real time RT-PCR. N=2; 
mice analyzed per group=5. B: Arg I expression analysis by flow cytometry in CD11b+ cells 
isolated form metastatic lungs expressed in % of positive cells (Left) and mean fluorescence 
intensity (MFI, right). C: Arg I expression analysis by flow cytometry in CD11b+Gr1LowLy6C+ 
and CD11b+Gr1HighLy6G+ cells in the blood, tumor and metastatic lungs. CD11b+Ly6C+ and 
CD11b+Ly6G+ cells are 100% positive for Arg I expression. Level of expression is highest in 
blood, intermediate in tumor and low in lung. N=2; mice analyzed per group=4. MFI, mean 
fluorescence intensity.  
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Figure	  S6.	  Immunostaining	  for	  Arg	  I,	  CD31	  and	  CD11.	  A,	  B:	  Tumors	  (A)	  and	  lungs	  (B)	  from	  control	  
IgG	   and	  CD101-­‐treated	  mice	  were	   stained	  with	   an+bodies	   to	   	   Arg	   I,	   CD31	   and	  CD11b.	  DC101	  
treatment	  decreases	  microvascular	  denisty	  and	  increased	  Arg	  I	  posi+ve	  cells	  in	  the	  lesions.	  Scale	  
bars:	  upper	  raws,	  1000	  μm;	  lower	  raws	  250	  μm.	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Figure S7. Nor-NOHA treatment does not affect primary tumor growth. 
A: Growth curves of 4T1 tumors in mice treated with Nor-NOHA or PBS. B: 
Quantification of tumor microvascular density (MVD) performed on 4-6 
representative images derived from both treatment groups. C: 
Quantification of tumor necrosis by H&E staining and morphometric 
analysis. Nor-NOHA-treated mice: 4T1+Nor-NOHA; control treated mice: 
4T1+PBS. N=1-2, mice analyzed per group = 7-10. 
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Figure S8. Effect of DC101 on inhibitory activity of in vitro generated BM-
MDSC. MDSC were generated in vitro by exposing bone marrow progenitor cells to 
GM-CSF and IL6 during 3 days. DC101 or control IgG were added during the 3 
days (3d) or at the last day (1d) of culture, as indicated. They were positively 
isolated by MACS and mixed with stimulated T cells at the indicated ratios. Results 
from one representative experiment per condition is shown; analysis done in 
triplicate.  
